immatics biotechnologies GmbH to Present at CIMT Annual Meeting 2013 in Mainz, Germany
5/13/2013 10:16:12 AM
More...
|
immatics biotechnologies GmbH' CSO to Present in Major Symposium at 2013 American Association for Cancer Research Annual Meeting in Washington D.C.
4/4/2013 9:55:34 AM
More...
|
immatics biotechnologies GmbH's Co-Founder Professor Dr Hans-Georg Rammensee Awarded the Bayer AG (BAY.F) Hansen Family Award 2013
3/7/2013 10:59:44 AM
More...
|
immatics biotechnologies GmbH Appoints Peter Chambre as Chairman
11/12/2012 1:10:08 PM
More...
|
immatics biotechnologies GmbH's Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted U.S. Orphan Drug Designation by the FDA
11/8/2012 2:26:58 PM
More...
|
immatics biotechnologies GmbH Announces Publication of IMA901 Cancer Vaccine Data in Nature Medicine: Immune Response Associates With Longer Survival
7/30/2012 10:38:37 AM
More...
|
immatics biotechnologies GmbH Presents Positive Phase II Results With its Therapeutic Cancer Vaccine IMA910 in Patients With Advanced Colorectal Cancer at the 2012 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
1/24/2012 7:12:59 AM
More...
|
immatics biotechnologies GmbH Raises EUR54 Million ($71 Million) to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio
9/21/2010 6:39:42 AM
More...
|
Scancell Enters Research Collaboration With immatics biotechnologies GmbH To Develop Novel Immunobody(R) Vaccines For Colorectal Cancer
6/29/2010 7:44:45 AM
More...
|
immatics biotechnologies GmbH Significantly Improves XPRESIDENT(TM) Technology Platform
6/17/2009 11:35:46 AM
More...
|
|